Updates are available Correction dated 2024-07-27
Click to view Correction: https://doi.org/10.1186/s13195-024-01538-0
-
Authors
Arranz, Javier
Zhu, Nuole
Rubio-Guerra, Sara
Rodríguez-Baz, Íñigo
Ferrer, Rosa
Carmona-Iragui, María
Barroeta, Isabel
Illán-Gala, Ignacio
Santos-Santos, Miguel
Fortea, Juan
Lleó, Alberto
Tondo, Mireia
Alcolea, Daniel
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (Rio Hortega, Rio Hortega, Rio Hortega, PI18/00335 to MCI, Juan Rodés Contract (JR20/0018), Juan Rodés contract JR18-00018; Fondo de investigación sanitaria grant PI19/00882, PI14/01126, PI17/01019 and PI20/01473 to JF, PI17/01896 and AC19/00103to AL, PI18/00164; PI21/00140, PI18/00435 and INT19/00016)
Global Brain Health Institute (Atlantic Fellows for Equity in Brain Health at the Global Brain Health Institute)
Alzheimer’s Association (ALZ UK-21-720973)
Alzheimer’s Society (AACSF-21-850193)
Alzheimer's Association (Alzheimer’s Association clinician scientist fellowship (AACSF-22-972945))
NIH (National Institutes of Health (R01AG080470))
National Institutes of Health (NIA grants 1R01AG056850-01A1; R21AG056974; and R01AG061566 to JF)
Fundació la Marató de TV3 (20141210 to JF, 20142610 to AL)
Pla Estratègic de Recerca i Innovació en Salut
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (Program 1, Alzheimer Disease to AL)
Generalitat de Catalunya
Fundación Tatiana
Fondo Europeo de Desarrollo Regional
Pla Estratègic de Recerca i Innovació en Salut (PERIS SLT006/17/125)
- License Information
-
More Information
Article History
Received: 8 December 2023
Accepted: 20 June 2024
First Online: 26 June 2024
Change Date: 27 July 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13195-024-01538-0
Declarations
:
: The ethics committee of Hospital Sant Pau approved all procedures included in this study following the standards for medical research in humans recommended by the Declaration of Helsinki. All participants or their legally authorised representative gave written informed consent before enrolment in the study.
: All authors revised the manuscript for content and provided critical feedback.
: Daniel Alcolea is employed by Hospital de la Santa Creu i Sant Pau and received research grants from Pla Estratègic de Recerca i Innovació en Salut (PERIS SLT006/17/125), and from Instituto de Salud Carlos III (PI18/00435 and INT19/00016). He participated in advisory boards from Fujirebio-Europe and Roche Diagnostics and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Zambon S.A.U., Esteve, and from Krka Farmacéutica S.L.Javier Arranz is employed by Biomedical Research Institute Sant Pau. He is funded by a “Rio Hortega” research grant from the Institute of Health Carlos III. Declarations of interest: none.Nuole Zhu is employed by Biomedical Research Institute Sant Pau. He is funded by a “Rio Hortega” research grant from the Institute of Health Carlos III. Declarations of interest: none.Sara Rubio-Guerra is employed by Hospital de la Santa Creu i Sant Pau. Declarations of interest: none.Iñigo Rodríguez-Baz is employed by Biomedical Research Institute Sant Pau. He is funded by a “Rio Hortega” research grant from the Institute of Health Carlos III. Declarations of interest: none.Rosa Ferrer is employed by Hospital de la Santa Creu i Sant Pau. Declarations of interest: none.María Carmona-Iragui is employed by Hospital de la Santa Creu i Sant Pau. Declarations of interest: none.Isabel Barroeta is employed by Hospital de la Santa Creu i Sant Pau. Declarations of interest: none.Dr. Illán-Gala is a senior Atlantic Fellows for Equity in Brain Health at the Global Brain Health Institute (GBHI), and is supported with funding from GBHI, Alzheimer’s Association, and Alzheimer’s Society (GBHI ALZ UK-21–720973 and AACSF-21–850193). Dr Illán-Gala was also supported by the Juan Rodés Contract (JR20/0018) and Fondo de Investigaciones Sanitario, (PI21/00791) from Instituto de Salud Carlos III.Ignacio Illán-Gala reported receiving personal fees from Nutricia, Esteve, UCB, and Neuraxpharm Spain outside the submitted work.Miguel Santos-Santos is employed by Hospital de la Santa Creu i Sant Pau. His research is supported by funding from the Spanish Institute of Health Carlos III (Juan Rodés contract JR18-00018; Fondo de investigación sanitaria grant PI19/00882), the Alzheimer’s Association clinician scientist fellowship (AACSF-22–972945), and the National Institutes of Health (R01AG080470).Juan Fortea is employed by Hospital de la Santa Creu i Sant Pau and received research grants from Institute of Health Carlos III, National Institutes of Health, Fundació La Marató de TV3, and Pla Estratègic de Recerca i Innovació en Salut (PERIS). Dr. Fortea has served as a consultant for Novartis and Lundbeck, has received honoraria for lectures from Roche, NovoNordisk, Esteve and Biogen and served at advisory boards for AC Immune, Zambon and Lundbeck.Alberto Lleó is employed by Hospital de la Santa Creu i Sant Pau and received research grants from CIBERNED, Institute of Health Carlos III, Generalitat de Catalunya (PERIS and AGAUR) and Fundación Tatiana and BBVA. He participated in advisory boards from Biogen, Eisai, Fujirebio-Europe, Novartis, NovoNordisk, Nutricia, Otsuka Pharmaceutical, and Zambón, and received speaker honoraria from Lilly, Biogen, KRKA and Zambon.Mireia Tondo is employed by Hospital de la Santa Creu i Sant Pau and has received research grants from Instituto de Salud Carlos III (PI18/00164; PI21/00140) and has served as consultant in Araclon.
